Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06463652
Other study ID # 08/24/DD-BVMD
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date October 2026

Study information

Verified date June 2024
Source M? Ð?c Hospital
Contact Thanh V Le, MD
Phone +84934124733
Email bsthanh.lv@myduchospital.vn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compares the effectiveness of cervical cerclage with vaginal progesterone to vaginal progesterone only for the prevention of preterm birth in women with a singleton pregnancy and a short cervical length. Participants will be randomly assigned in a 1:1 ratio to receive cerclage plus progesterone or progesterone only.


Description:

This open-label, multi-center, randomized controlled trial aims to compare the effectiveness of cervical cerclage with vaginal progesterone (the combined therapy group) to vaginal progesterone only (the progesterone-only group) for the prevention of preterm birth in women with a singleton pregnancy and a cervical length ≤ 25mm. After written informed consent, women will be randomly assigned in a 1:1 ratio to receive a cervical cerclage with vaginal progesterone or vaginal progesterone only. Randomization will be carried out by entering participant details into HOPE Epi® (a web portal of HOPE Research Center, My Duc Hospital). Treatment allocation will be assigned according to a computer-generated randomization list stored in the online system, with a permuted random block size of 2, 4, or 6. Blinding will not be possible due to the nature of interventions. However, neonatologists assessing the neonates will be unaware of treatment allocation. Apart from randomization, participants will be monitored and treated according to local protocol. All women at 16 0/7 to 24 0/7 weeks' gestation with a singleton pregnancy will undergo cervical length measurement and digital examination at screening routinely. Women with a cervical length ≤25 mm will be eligible for the study. Eligible women will further undergo a speculum examination to assess the feasibility of treatment with either cervical cerclage or vaginal progesterone and to exclude premature rupture of the membranes, acute vaginitis, and cervicitis. Only women in whom the clinician assesses both treatments as feasible will be randomized. Women allocated to a combined therapy group will receive the intervention according to local protocol within a week after randomization. Briefly, cervical cerclage (McDonald technique) will be performed in the operation theatre. From the same day of undergoing cerclage, participants will be receiving 200 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 200mg, Actavis, United Kingdom), once daily at bedtime. Participants will be asked to record their drug application in a participant diary sheet. Women allocated to the progesterone-only group will be receiving 200 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 200mg, Actavis, United Kingdom), once daily at bedtime. Participants will be asked to record their drug application in a participant diary sheet. In both groups, interventions will be stopped at 37 0/7 weeks of gestation or at delivery. Primary analysis will be performed on an intention-to-treat basis. The primary outcome, the time from randomization to delivery, will be summarised as median and IQR and compared between the two arms using the Mann-Whitney test. A mean ratio with a 95% confidence interval will be calculated to assess the effect of the treatment. Kaplan-Meier and Cox proportional hazard analysis will be performed in which the gestational week at delivery will be the time scale, continued pregnancy will be the event, and results will be compared with a log-rank test. Hazard ratio (HR) values will be estimated using a Cox proportional hazards model, with a formal test of the proportional hazard assumption. The secondary outcome will be analysed by reporting continuous variables as mean and standard deviation for normally distributed variables or median and interquartile range (Q1; Q3) for non-normally distributed variables. Categorical variables will be presented as the number of events and proportions. Student T-test or Mann-Whitney U test will be used for continuous outcomes to compare the differences between groups. For categorical outcomes, the Chi-squared or Fisher exact test will be used. In the case of dichotomous endpoints, the relative risk (RR) and 95% confidence interval (CI) values will be calculated using the Wald or Adjusted Wald methods for a small proportion. Per-protocol analysis will also be conducted if needed. A prespecified subgroup analysis will be performed by quartiles of cervical length, which tested for interaction between cervical length and the treatment effect on the primary outcome, the major secondary outcome and PTB <28, <34, <37 weeks. The p-values <0.05 will be considered to indicate statistical significance. Statistical analyses will be performed using the R statistical software. Details of the analysis will be described in a separate statistical analysis plan developed during the study and finalized before the data lock. Cost data will be collected and will be reported on a separated paper. Interim analysis will be done after completion of data recruitment of the first 162 participants, by an independent Data Safety Monitoring Committee. The Data Safety Monitoring Committee will be asked to assess the primary endpoint for effectiveness. Also, the Data Safety Monitoring Committee will be provided insight into the serious adverse events (SAEs) that have occurred. The interim analysis will be conducted using a two-sided significant test with the Haybittle-Peto spending function and a type I error rate of 5 percent with p <0.001 (Z alpha = 3.29) being a reason to stop the trial. The continuation of the study will depend on the advice of Data Safety Monitoring Committee.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 328
Est. completion date October 2026
Est. primary completion date May 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Maternal age =18 years - Singleton pregnancy - Cervical length = 25 mm, measured by TVS at the second-trimester ultrasonography (16 0/7 - 24 0/7 weeks of gestation) - Not participating in any other study which has intervention on maternity or fetus - Provision of written informed consent as shown by a signature on the participant consent form. Exclusion Criteria: - Cervical dilation with visible amniotic membranes or amniotic membranes prolapsed into the vagina - Major congenital abnormalities of the fetus - Intrauterine fetal demise - Presence of severe vaginal discharge* - Presence of vaginitis or cervicitis* - Presence of vaginal bleeding* - Placenta previa or vasa previa - Preterm premature rupture of membranes - Preterm labor without ruptured membrane at the time of screening - Suspected chorioamnionitis - Unable to undergo cerclage - Cerclage in place - Allergy to progesterone (*Women with acute cervicitis, vaginitis or severe vaginal discharge are eligible once they have been treated and if they have a CL =25 mm between 16 0/7 - 24 0/7 weeks of gestation.)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cervical cerclage
Cervical cerclage using the McDonald technique under anaesthesia.
Drug:
Vaginal progesterone
Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.

Locations

Country Name City State
Vietnam My Duc Hospital Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
M? Ð?c Hospital

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time from randomization to delivery Number of days between randomization and delivery From date of randomization until the date of delivery
Secondary Composite poor neonatal outcomes (major sencondary endpoint) Stillbirth or neonatal death, intraventricular haemorrhage, respiratory distress syndrome, necrotizing enterocolitis or neonatal sepsis. From 20 weeks of gestation to 28 days after estimated due date
Secondary Miscarriage <22 weeks (late miscarriage) spontaneous loss of pregnancy between 12 to 22 weeks is termed as late miscarriage From date of randomization to 22 weeks of gestation
Secondary Gestational age at delivery Gestational age at delivery At delivery
Secondary Preterm birth <24 weeks, <28 weeks, <32 weeks, <34 weeks and <37 weeks of gestation Preterm birth is defined as any birth = 22 and < 37 completed weeks of gestation. Any birth < 22 weeks is defined as late miscarriage At delivery
Secondary Spontaneous preterm birth <24 weeks, <28 weeks, <32 weeks, <34 weeks and <37 weeks of gestation Spontaneous preterm birth, including preterm labour, preterm spontaneous rupture of membranes, preterm premature rupture of membranes, and cervical weakness before 24 weeks, 28 weeks, 32 weeks, 34 weeks, and 37 weeks of gestation, respectively, does not include indicated preterm delivery for maternal or fetal conditions. At delivery
Secondary Iatrogenic preterm birth <24 weeks, <28 weeks, <32 weeks, <34 weeks and <37 weeks of gestation Iatrogenic preterm birth, including planned delivery that occurs before 24 weeks, 28 weeks, 32 weeks, 34 weeks, and 37 weeks of gestation, respectively, due to maternal and/or fetal causes. At delivery
Secondary Onset of labor Classified as spontaneous, labor induction, or elective C-section. At birth
Secondary Mode of delivery Classified as vaginal delivery or C-section (elective, suspected fetal distress, non-progressive labor). At birth
Secondary Live birth Defined as the complete expulsion or extraction from a woman of a product of fertilization after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown At birth
Secondary Use of tocolytic drugs Use of any tocolytic drug to treat preterm labour From 24 0/7 to 33 6/7 weeks' gestation
Secondary Use of Post cerclage antibiotics Use of any treatment antibiotics after the cerclage procedure Within one week after the cerclage procedure
Secondary Use of antenatal corticosteroids Use of antenatal corticosteroids to prevent respiratory distressed syndrome From 24 0/7 to 33 6/7 weeks' gestation
Secondary Use of MgSO4 for neuroprotection Use of MgSO4 for neuroprotection From 24 0/7 to 31 6/7 weeks' gestation
Secondary Fetal growth restriction It is defined as the failure of the fetus to meet its growth potential due to a pathological factor, most commonly placental dysfunction. From randomization to delivery
Secondary Preterm premature rupture of membranes When membrane rupture occurs before labor and before 37 weeks of gestation From randomization to before 37 weeks of gestation
Secondary Length of maternal admission for labour Number of maternal admission days for labour Up to 2 weeks after birth
Secondary Total length of admission for threatened preterm labor Number of admission days for treatment of preterm labour From 22 0/7 to 36 6/7 weeks of gestation
Secondary Chorioamnionitis Intraamniotic infection (diagnosed according to The American College of Obstetricians and Gynecologists Committee on Obstetric Practice No 712, 2017 (reaffirmed 2022)) From randomization to delivery
Secondary Maternal mortality female deaths from any cause related to or aggravated by pregnancy or its management (excluding accidental or incidental causes) during pregnancy and childbirth or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy From randomization to during pregnancy and childbirth or within 42 days of termination of pregnancy
Secondary Maternal side effects Vaginal discharge, vaginal bleeding, vaginal infection (confirmed by vaginal discharge culture), preterm premature rupture of membranes, chorioamnionitis, necrosis or rupture of the cervix, cervical laceration, vaginal or bladder injury. From date of randomization until delivery
Secondary Birthweight Weight of the newborn measured right after delivery At birth
Secondary Birthweight <1500 g Weight of the newborn <1500g At birth
Secondary Birthweight <2500 g Weight of the newborn <2500g At birth
Secondary Congenital anomalies Structural or functional disorders that occur during intra-uterine life and can be identified prenatally and at birth. Congenital anomalies can be caused by single gene defects, chromosomal disorders, multifactorial inheritance, environmental teratogens, and micronutrient deficiencies. The time of identification will be reported. After randomization to at birth
Secondary 1-min Apgar score Apgar score at 1 minute after birth 1 min after birth
Secondary 5-min Apgar score Apgar score at 5 minute after birth 5 min after birth
Secondary Admission to neonatal intensive care unit Admission to neonatal intensive care unit of baby At birth and up to 28 days after birth
Secondary Length of stay in the neonatal intensive care unit Number of admission days to neonatal intensive care unit Up to 28 days after estimated due date
Secondary Neonatal death Death of a live-born baby within 28 days of birth Within the first 28 days of life after delivery
Secondary All stillbirth Defined as the death of a fetus prior to the complete expulsion or extraction from its mother after 20 completed weeks of gestational age. The death is determined by the fact that, after such separation, the fetus does not breathe or show any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles. It includes deaths occurring during labor.
All stillbirth will be defined as a baby born with no signs of life at = 20 weeks of gestation
After 20 weeks of gestation
Secondary Early stillbirth A baby born with no signs of life at = 20 weeks and < 28 weeks of gestation = 20 weeks and < 28 weeks of gestation
Secondary Late stillbirth A baby born with no signs of life at = 28 weeks of gestation After 28 weeks of gestation
Secondary Perinatal death Either stillbirth or neonatal death From 20 weeks of gestation to the first 28 days of life after delivery
Secondary Respiratory distress syndrome Diagnosed as the presence of tachypnoea >60/minute, sternal recession and expiratory grunting, need for supplemental oxygen, and a radiological picture of diffuse reticulogranular shadowing with an air bronchogram Up to 28 days after estimated due date
Secondary Intraventricular haemorrhage II B or worse Diagnosed by repeated neonatal cranial ultrasound by the neonatologist according to the guidelines on neuro-imaging described by de Vries et al Up to 28 days after estimated due date
Secondary Necrotizing enterocolitis An acquired gastrointestinal disease associated with significant morbidity and mortality in prematurely born neonates. Necrotizing enterocolitis will be diagnosed according to Bell et al., 1978 Up to 28 days after estimated due date
Secondary Neonatal sepsis Diagnosed on the combination of clinical signs and positive blood cultures of the newborn Up to 28 days after estimated due date
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04021654 - What is the Future of Vulnerable New-borns